OBI Pharma, Inc. on behalf of OBIGEN announced TFDA clearance of IND application for a phase II human clinical trial evaluating OBI-858 treatment for subjects with moderate to severe frown. After obtaining official approval or the results of statistically significant sense, the future strategy: Proceed to Phase II human clinical trial; Accumulated investment expenditure incurred: For negotiation on potential licensing deals in the future, and for the best interest of shareholders, this information is kept confidential temporarily. Upcoming development plan: Phase II clinical trial; Estimated date of completion: 2025.

Estimated responsibilities: Clinical trial related R&D expenses.